Stay updated with breaking news from Enabling Studies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for... | May 15, 2023
09.08.2022 - Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025 Patient Dosing Underway with Lead Candidate, VERVE-101, for Treatment of Heterozygous Familial Hypercholesterolemia; Regulatory ...
Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
KU Leuven enters international licence agreement on cancer therapy These updates are republished press releases and communications from members of the Science|Business Network TEAD inhibition holds great promise as a therapeutic approach as the Hippo pathway is genetically altered in up to 10% of cancers. In mesothelioma, an aggressive and untreatable cancer often caused by asbestos exposure, 60 to 70% of patients have mutations in the Hippo pathway leading to striking sensitivity to TEAD-inhibitors. SpringWorks Expects to Nominate a Development Candidate and Commence IND-E...